Jilin Aodong Pharmaceutical Group Co., Ltd.: history, ownership, mission, how it works & makes money

From its origins in 1957 as the state-owned Yanbian Dunhua Deer Farm to its 1996 Shenzhen listing under ticker 000623.SZ, Jilin Aodong Pharmaceutical Group has grown into a diversified healthcare and industrial conglomerate whose balance sheet showed total assets of ¥33.002 billion and net assets of ¥29.282 billion at the end of 2024; controlled primarily by Dunhua Jincheng Industry Co., Ltd. with a 27.35% stake, other notable holders include GF Securities (3.62%), the first-phase employee stock ownership plan (2.15%), Agricultural Bank of China CSI 500 ETF (1.03%) and Hong Kong Securities Clearing (0.87%), while its operating footprint spans three modern bases-the Jilin Aodong Industrial Park (Dunhua), the High-tech Pharmaceutical Park (Yanji) and the Phytochemical Park (Taonan)-and a business model that mixes pharmaceutical R&D and manufacturing (oral liquids, injections, capsules, traditional Chinese medicines, enzymes and plant chemical medicines) with highway construction/toll collection, animal husbandry, specialty chemicals, real estate and utilities; the company promotes the mission of providing "safe, reliable, and trustworthy medicine" and carries honors such as designation as a National High‑Tech Enterprise, inclusion among China's 500 Most Valuable Brands and the National May 1 Labor Merit Certificate, and as of November 18, 2025 its market capitalization stood at ¥23.75 billion with trailing‑12‑month revenue of ¥2.34 billion and net income of ¥2.57 billion.

Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ): Intro

• 1957 - Established as the state-owned Yanbian Dunhua Deer Farm, marking the company's origin in Jilin province and its initial entry into bio/pharmaceutical resources.
• 1981 - Expanded operations with the founding of Aodong Pharmaceutical Factory, beginning focused production of medicinal products.
• 1993 - Major restructuring created Yanbian Aodong Pharmaceutical (Group) Co., Ltd., consolidating operations into a group structure to support growth and diversification.
• 1996-10-28 - Listed on the Shenzhen Stock Exchange (ticker: 000623.SZ), providing public capital and market visibility.
• 1998 - Renamed Jilin Aodong Pharmaceutical Group Co., Ltd., reflecting broader strategic orientation and provincial identity.
• 2001 - Adopted a parent-subsidiary corporation system, establishing the holding-group listed-company structure centered on pharmaceuticals.
• By end-2024 - Reported total assets of 33.002 billion yuan and net assets of 29.282 billion yuan, demonstrating substantial scale and balance-sheet strength.

• Mission - Develop, manufacture and commercialize accessible, quality pharmaceutical products while leveraging traditional bio-resources and modern pharmaceutical R&D.
• Strategic focus - Integrated pharmaceutical group with manufacturing, product development, commercialization and distribution capabilities across human and veterinary medicines, health products and raw-medicine processing.
• R&D and production capacity - Operates multiple production facilities and R&D centers (domestic manufacturing footprint supporting prescription and OTC portfolios), with ongoing investment to meet GMP and regulatory standards.

• Research & development - In-house formulation and clinical development for generics, specialty drugs and health supplements; partnerships/licensing for technology and compound pipelines.
• Manufacturing - Multi-site production covering APIs, finished-dose formulations, and derived health products, supplying both domestic markets and selected export channels.
• Regulatory & quality control - Compliance with national GMP and regulatory registration processes; quality assurance is central to market access for prescription and OTC medicines.
• Commercialization & distribution - Sales through hospital procurement, pharmacy chains, distributors, e-commerce and export customers; marketing teams manage therapeutic and OTC brands.
• Support functions - Procurement of raw materials (including biological resources historically tied to its origins), cold-chain/logistics, and M&A or JV activities to expand portfolios and geographic reach.

• Drug sales - Core revenue from prescription medicines and over‑the‑counter products sold to hospitals, pharmacies and distributors.
• Health products & supplements - Sales of consumer health products and nutraceuticals leveraging brand and distribution networks.
• Contract manufacturing & APIs - Income from producing active pharmaceutical ingredients and contract manufacturing for third parties.
• Exports & licensing - Cross‑border sales and licensing or partnership revenues from joint ventures, technology transfers or product co-development.

• Listed equity - Publicly traded since 1996 on SZSE under 000623.SZ, providing access to equity capital markets for expansion, R&D and M&A.
• Balance sheet strength - Total assets of 33.002 billion CNY and net assets of 29.282 billion CNY at end-2024 indicate a conservative leverage profile and substantial equity base to support operations and investment.

• Parent-subsidiary holding model in place since 2001 to centralize strategy while permitting operational autonomy at subsidiary level.
• Group structure enables focused investment in pharmaceutical manufacturing, R&D, and downstream commercialization channels.

Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ): History

• Founded and early development: regional API and generic drug manufacturing, 1990s-2000s.
• Capacity expansion and modernization: investment in GMP plants and R&D in the 2010s.
• Strategic shift: increased emphasis on finished formulations and specialty products, 2015-present.

Ownership Structure

• Major strategic investor: Dunhua Jincheng Industry Co., Ltd. - 27.35%.
• Broker/investment firm participation: GF Securities Co., Ltd. - 3.62%.
• Employee alignment: first phase ESOP - 2.15%.
• Passive/index investors: Agricultural Bank of China Ltd. - CSI 500 ETF - 1.03%.
• Cross-border/intermediary: Hong Kong Securities Clearing Company Limited - 0.87%.

Mission

How It Works & Makes Money

• API production: sale of active pharmaceutical ingredients to domestic and international drugmakers (volume-driven, cost-competitive).
• Finished formulations: tablets, capsules, injectables sold to hospitals, distributors, and retail pharmacies (higher-margin than APIs).
• Biologics and specialty drugs: R&D-backed products with pricing that reflects differentiation and IP protection.
• Contract manufacturing and toll-processing: capacity monetization for third parties.
• Export sales: selected overseas markets, leveraging scale in APIs and formulations.

Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ): Ownership Structure

• Mission: Provide safe, reliable, trustworthy medicine; carry forward 'relieving the world.'
• Values: Patient safety, product quality, technological innovation, social responsibility.
• Strategic focus: R&D-driven pharmaceutical manufacturing, quality control, and expanded market distribution domestically and regionally.

• Largest shareholder: Jilin Aodong Group (majority / controlling stake - material single shareholder influence).
• Public shareholders / free float: significant portion listed on Shenzhen Stock Exchange providing liquidity and market discipline.
• Management & Board: professional executive team with R&D and manufacturing backgrounds, overseen by a board balancing state/group interests with independent directors.

• Product mix: finished pharmaceuticals (cardio‑metabolic, anti‑infection, traditional Chinese medicine formulations), bulk APIs, and OTC consumer health items-sales diversified across hospital channels, retail pharmacies and distributors.
• R&D & high‑tech positioning: National High‑Tech Enterprise status supports investment in formulation upgrades, process patents and quality systems that protect margins and market access.
• Revenue drivers: hospital procurement contracts, regional distribution agreements, branded OTC sales, and growing export channels to neighboring markets.

Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ): Mission and Values

• Core industrial bases:
  • Jilin Aodong Industrial Park - Dunhua City (manufacturing and chemical intermediates)
  • Jilin Aodong High-tech Pharmaceutical Park - Yanji City (formulations, R&D)
  • Jilin Aodong Phytochemical Pharmaceutical Park - Taonan City (plant-extract APIs and phytochemicals)
• Business scope spans pharmaceuticals (APIs, formulations), phytochemicals, specialty chemicals, animal husbandry inputs, utility supply (heat/water), vehicle rental, self-owned real estate operations, highway construction and toll collection, plus wholesale/retail/distribution of medicines.

• Integrated manufacturing cluster: By concentrating production across three specialized parks, Jilin Aodong achieves economies of scale, higher utilization of intermediate products (APIs → formulations), and lower logistics costs between sites.
• Product and technology upgrade cycle: Continuous investment in pharmaceutical R&D and process upgrading increases product mix value (shift toward higher-margin formulations and patented or niche phytochemical products) and strengthens consumer trust.
• Diversified cash-flow portfolio: Non-pharma activities (vehicle rental, real estate leasing, highway toll operations, heat/water supply, animal husbandry inputs, specialty chemicals) provide counter-cyclical revenue streams and stable fee-based income components.
• Distribution and channel control: Wholesale, retail and distribution networks for medicines capture margin beyond manufacturing and allow faster market rollout for new products.

• Clustered production reduces per-unit cost through shared utilities, logistics and procurement.
• Phytochemical park provides upstream control of plant-based APIs, improving margin and product differentiation.
• Multi-segment revenue mix lowers single-market exposure-toll and leasing revenues add recurring cash inflows.
• Investment in technological upgrading supports regulatory compliance and market trust, enabling premium pricing on quality drugs and specialty products.

Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ): How It Works

• Core pharmaceutical manufacturing: oral liquids, injections, capsules, granules, pills, tablets, syrups, powders, tonic medicines and spirits, and Chinese herbal medicines.
• Biotech & specialty: enzymes, biochemical medicines, plant chemical medicines and specialty chemicals.
• Non-pharmaceutical operations: highway construction and toll collection, animal husbandry, heat and water supply, wholesale/retail and distribution networks.

• Manufacturing & sales: contract manufacturing and in-house brands sold through hospitals, pharmacies and distributors-prices set by product class (generic vs. speciality), procurement tenders and national medical insurance listings.
• R&D and product lifecycle: incremental margin growth on novel formulations and higher-value injectable/biochemical products; TCM and tonic products often enjoy stable demand and regional brand recognition.
• Distribution & retail: markup and service fees through distribution arm; logistics and warehousing reduce channel costs and capture margin.
• Infrastructure & tolls: periodic toll receipts from operated highway assets provide recurring non-cyclical cash flow.
• Agriculture & husbandry: sale of livestock and related by-products-supplementary revenue and vertical integration for raw material sourcing in some products.
• Utilities & services: heat and water sales to industrial and residential customers near group facilities; steady operating income with regulated returns.

• Oral liquids, syrups and tonic medicines: stable high-volume revenue, important for regional market share.
• Injections and biochemical medicines: higher-margin specialty segment-key driver of margin expansion when scaled.
• Traditional Chinese medicines (herbal formulations, spirits): brand-driven, steady margins and customer loyalty.
• Specialty chemicals & enzymes: sold to industrial and pharmaceutical clients-adds product diversification and margin smoothing.
• Highway tolls and infrastructure returns: low-volatility cash flow that offsets pharma cyclical trends.
• Animal husbandry products: supplemental revenue and potential vertical supply benefits for certain raw materials.
• Utilities and distribution services: service revenue plus operational leverage through group-owned logistics and supply chains.

• Scale manufacturing footprint-leveraging multiple production lines to achieve lower unit costs for mass-market generics and TCM products.
• Procurement and tendering-competing for hospital and provincial tender contracts, where winning larger tenders drives volume and utilization.
• Brand & channel control-own distribution reduces third-party margins and secures shelf space in pharmacies and hospital supply chains.
• Asset-backed diversification-toll roads and utility assets produce recurring cash flows used to finance capex and stabilize earnings.
• Cross-segment synergies-use of agricultural outputs and specialty chemicals within manufacturing to reduce input cost exposure.

• Sales volume growth in injections and biochemical products (indicator of margin improvement).
• Proportion of revenue from non-pharma segments (tolls, utilities)-higher share implies lower pharma cyclicality.
• Gross and operating margins trend-shows product mix shift toward higher-value items.
• R&D pipeline approvals and inclusion in national/provincial procurement lists-affects pricing and volume potential.
• Debt levels and cash flow from toll operations-important for investment capacity and financial stability.

Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ): How It Makes Money

• Core pharmaceutical manufacturing: bulk cardiovascular, anti-infective and proprietary formulations sold to hospitals, distributors and retail pharmacies.
• Finished dosage forms & contract manufacturing (CMO): production services for third parties and in-house brands.
• Pharmaceutical distribution and logistics: warehousing, cold-chain and downstream sales channels enhancing market reach.
• Infrastructure and investment operations: real-estate related services and industrial park operations providing non-cyclical income.
• R&D-driven specialty drugs and upgraded formulations: higher-margin pipeline products targeting market premiumization.

• Revenue stability stems from a balance of low-volatility infrastructure/investment income and cyclical pharmaceutical sales.
• Profitability drivers include premiumization (innovation/new formulations), capacity utilization in manufacturing and higher-margin CMO contracts.
• Risk mitigants: diversified segments, recognized brand status and ongoing tech upgrades that support pricing power and market access.